In a genetic association study, investigators integrated data from genome-wide association studies of various disorders with retinal transcriptomic data. Findings revealed that the polygenic risk of ...

Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing ...

Dr Sunir Garg reflects on the recent American Academy of Ophthalmology meeting in Orlando and expresses excitement on how artificial intelligence (AI) can be used to detect, treat, and transform the ...

Sunir Garg, MD, expresses excitement about attending AAO 2025 and focuses on several topics to be discussed. These include the benefits and potential vision risks of GLP-1 inhibitors in patients with ...

Retinal diseases are at the forefront of a quiet revolution in the realm of ophthalmology. Gene therapy, once a distant dream, is now emerging as a beacon of hope for millions affected by these ...

Population-based studies have shown retinal disorders are the most common cause of irreversible blindness in developed countries and the second most common cause of blindness after cataracts in ...

A new study by Brown University researchers suggests that gold nanoparticles—microscopic bits of gold thousands of times thinner than a human hair—might one day be used to help restore vision in ...

Millions of people suffer from retinal disorders, such as macular degeneration and retinitis pigmentosa. A new study suggests that injecting gold nanoparticles into the retina and stimulating those ...

Partnership Leverages PolyActiva’s PREZIA™ Drug Delivery Platform Technology and RareSight’s Expertise in Rare Diseases to Advance Novel Sustained Release Ocular Implants PolyActiva, a clinical-stage ...

In a study published in the journal ACS Nano and supported by the National Institutes of Health, the research team showed that nanoparticles injected into the retina can successfully stimulate the ...